Current Research Studies
A prospective, multicenter, open-label, single-arm, Phase 2 study to investigate the safety, tolerability and pharmacokinetics of Selexipag in children with pulmonary arterial hypertension
Selexipag for Children with Pulmonary Arterial Hypertension
What is the goal of the study?
The primary objective of the study is to confirm the Selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, which leads to similar exposures as adult doses in children from ≥ 2 to ˂ 18 years of age, with pulmonary arterial hypertension (PAH), by investigating the PK of Selexipag and its active metabolite ACT-333679 in this population. Secondary objectives are to evaluate the safety and tolerability of Selexipag in children from ≥ 2 to ˂ 18 years of age with PAH. Site For Selexipag for Children with Pulmonary Arterial Hypertension
Who can participate in the study?
Please contact the study team listed below to learn more.